Exact Sciences announced performance data for its blood-based colorectal cancer (CRC) screening test at the European Society of Medical Oncology (ESMO) Congress, the company announced recently. According to a release,…
Exact Sciences shared new modeling data that shows the impact of the Cologuard tests on patients, healthcare professionals and the U.S. healthcare system since its FDA approval a decade ago,…
Exact Sciences is collaborating with the Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients, the company announced recently. According to a release, the Mayo Clinic…
Exact Sciences plans to submit next-generation Cologuard tests for FDA approval, the company announced recently. According to a release, the results from its BLUE-C study saw 94 percent sensitivity for…
Exact Sciences announced recently that it acquired PreventionGenetics, a clinical DNA testing laboratory located in Marshfield, Wis. According to a release, PreventionGenetics will provide the clinical lab, expertise and technology…
Exact Sciences and Jefferson Health are collaborating to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test, the company announced recently. According to a release, the joint effort…
Exact Sciences has acquired Ashion Analytics to help accelerate the development of its precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests, the company announced recently. According…
Exact Sciences announced today it will acquire Thrive Earlier Detection Corp. for $2.15 billion and Base Genomics for an undisclosed sum. Both companies specialize in cancer screening blood tests. According to…
Exact Sciences has introduced its Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory or recurrent cancer, the company announced today. According to a release, the Oncotype MAP…
Exact Sciences has extended and made amendments to its agreement with Pfizer to promote Cologuard, the company announced recently. “We’re thrilled to continue working with Pfizer to increase screening rates with…
